[1]张紫寅,邱 冬,唐雪松,等.原发性肝癌患者载药微球TACE术后近期疗效预测模型的建立[J].介入放射学杂志,2026,(03):313-318.[doi:10.3969/j.issn.1008-794X.2026.03.014]
　ZHANG Ziyin,QIU Dong,TANG Xuesong,et al.The establishment of a prediction model for predicting short-term effect of drug-loaded microspheres TACE in patients with primary hepatocellular carcinoma[J].J Intervent Med,2026,(03):313-318.[doi:10.3969/j.issn.1008-794X.2026.03.014]
点击复制

原发性肝癌患者载药微球TACE术后近期疗效预测模型的建立()

PDF下载中关闭

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2026年03
页码:
313-318
栏目:
临床研究
出版日期:
2026-03-25

文章信息/Info

Title:
The establishment of a prediction model for predicting short-term effect of drug-loaded microspheres TACE in patients with primary hepatocellular carcinoma
文章编号:
1008-794X(2026)-003-0313-06
作者:
张紫寅;  邱 冬;  唐雪松;  严智星;  杨四海;  袁 凯;  秦 伟;  姜永继
642350 四川安岳 安岳县人民医院介入科(张紫寅、邱 冬、唐雪松、严智星、姜永继); 广元市第二人民医院介入科(杨四海); 重庆医科大学附属遂宁市中心医院介入科(袁 凯、秦 伟)
Author(s):
ZHANG Ziyin; QIU Dong; TANG Xuesong; YAN Zhixing; YANG Sihai; YUAN Kai; QIN Wei; JIANG Yongji.
Department of Interventional Radiology,Anyue County People’s Hospital,Anyue,Sichuan Province 642350,China
关键词:
原发性肝癌;  载药微球;  肝动脉化疗栓塞术;  近期疗效;  预测模型
分类号:
R735.7
DOI:
10.3969/j.issn.1008-794X.2026.03.014
文献标志码:
B
摘要:
目的 调查原发性肝癌患者载药微球TACE术后近期疗效,并建立起预测模型。方法选择2019年1月至2024年1月在三家医院行TACE术治疗的原发性肝癌患者232例进行回顾性分析。收集可能影响原发性肝癌患者载药微球TACE近期疗效因素,根据疾病控制情况将患者分为控制组与未控制组,比较两组患者一般资料、疾病与手术相关因素、实验室指标,以LASSO回归筛选潜在变量后进行多因素logisitic回归分析建立预测模型,用列线图进行可视化,并对模型进行验证。结果 232例原发性肝癌患者中共有52例(22.41%)病情未控制。LASSO回归基础上进行多因素logistic回归分析结果显示:病灶数目、肿瘤边缘、门脉癌栓、包膜为原发性肝癌患者载药微球TACE近期疗效的独立性影响因素(P<0.05)。根据多因素分析结果建立预测模型,模型验证结果显示:模型组ROC曲线下面积为0.826,95%CI:0.756～0.895; 验证组ROC曲线下面积为0.803,95%CI:0.728～0.878。模型曲线与理想模型曲线基本拟合成对角线。临床有效性分析结果显示,当预测概率阈值0.10～0.75时,使用本研究模型预测原发性肝癌患者载药微球TACE近期疗效患者的净获益最高。结论 原发性肝癌患者载药微球TACE术后疗效主要受病灶数目、肿瘤边缘等因素的影响,该研究建立的预测模型可用于预测原发性肝癌患者载药微球TACE后近期疗效。

参考文献/References:

[1] 中国抗癌协会肿瘤微创治疗专业委员会,中国抗癌协会肿瘤消融治疗专业委员会.复合式冷热消融系统治疗原发性肝癌中国专家共识(2023)[J].介入放射学杂志,2023,32:949-953.
[2]中国抗癌协会肿瘤介入学专业委员会.药物洗脱微球治疗不可切除原发性肝癌的临床应用共识[J].中华放射学杂志,2022,56:349-355.
[3]Cao G,Gu J,Zhang H,et al.Transarterial chemoembolization using drug-eluting beads versus lipiodol in the treatment of unresectable hepatocellular carcinoma:propensity score matching[J].J Gastrointest Oncol,2024,15:1101-1111.
[4]Wei G,Yang J.Advances in the treatment of hepatocellular carcinoma using drug-eluting beads[J].J Interv Med,2020,3:122-127.
[5]刘 顺.TACE联合阿帕替尼治疗巴塞罗那C期肝癌疗效及影响因素分析[D].安徽医科大学,2022.
[6]Zhang H,Wu C,Chen M,et al.Drug-eluting bead transarterial chemoembolization(DEB-TACE)versus conventional transarterial chemoembolization(cTACE)in colorectal liver metastasis:Efficacy,safety,and prognostic factors[J].J Cancer Res Ther,2023,19:1525-1532.
[7]Wang Q,Zhu L,Sheng Q.Clinical research progress of callisperes of drug-loaded microsphere arterial chemoembolisation in the treatment of solid tumors[J].Discov Oncol,2024,15:161.
[8]Ma Y,Li Z,Luo Y,et al.Biodegradable microembolics with nanografted polyanions enable high-efficiency drug loading and sustained deep-tumor drug penetration for locoregional chemoembolization treatment[J].ACS Nano,2024,18:18211-18229.
[9]Yuan G,Liu Z,Wang W,et al.Multifunctional nanoplatforms application in the transcatheter chemoembolization against hepatocellular carcinoma[J].J Nanobiotechnology,2023,21:68.
[10]Duan X,Zhao G,Han X,et al.Arsenic trioxide-loaded CalliSpheres:in vitro study of drug release and antitumor activity,and in vivo study of pharmacokinetics,treatment efficacy and safety in liver cancer[J].Oncol Rep,2021,46:124.
[11]Pillai K,Ke K,Mekkawy A,et al.Enhancement of treatment efficacy of hepatic tumours using Trans-arterial-chemoembolization[J].Am J Cancer Res,2023,13:1623-1639.
[12]Nuzulia NA,Mart T,Ahmed I,et al.The us-e of microspheres for cancer embolization therapy:recent advancements and prospective[J].ACS Biomater Sci Eng,2024,10:637-656.
[13]Chen H,Cheng H,Wu W,et al.The blooming intersection of transcatheter hepatic artery chemoembolization and nanomedicine[J].Chin Chem Lett,2020,31:1375-1381.
[14]Shi L,Li D,Tong Q,et al.Silk fibroin-based embolic agent for transhepatic artery embolization with multiple therapeutic potentials[J].J Nanobiotechnology,2023,21:278.
[15]Zhai BT,Sun J,Shi YJ,et al.Review targeted drug delivery systems for norcantharidin in cancer therapy[J].J Nanobiotechnology,2022,20:509.
[16]Chen M,Xu X,Shu G,et al.Multifunctional microspheres dual-loaded with doxorubicin and sodium bicarbonate nanoparticles to introduce synergistic trimodal interventional therapy[J].ACS Appl Bio Mater,2021,4:3476-3489.
[17]Wei J,Tan Y,Bai Y,et al.Mesoporous silicon nanoparticles with liver-targeting and pH-response-release function are used for targeted drug delivery in liver cancer treatment[J].Int J Mol Sci,2024,25:2525.
[18]Miszczuk MA,Chapiro J,Geschwind JH,et al.Lipiodol as an imaging biomarker of tumor response after conventional transarterial chemoembolization:prospective clinical validation in patients with primary and secondary liver cancer[J].Transl Oncol,2020,13:100742.
[19]Rana MM,Melancon MP.Emerging polymer materials in trackable endovascular embolization and cell delivery:from hype to hope[J].Biomimetics(Basel),2022,7:77.
[20]de C Bittencourt DM,Oliveira PF,Souto BM,et al.Molecular dynamics of synthetic flagelliform silk fiber assembly[J].Macromol Mater Eng,2021,306:2000530.
(收稿日期:2024-09-25)
(本文编辑:茹 实)

相似文献/References:

[1]郭添胜,姜在波,黄明声,等.原发性肝癌合并糖尿病介入治疗的围手术期处理[J].介入放射学杂志,2000,(03):182.
[2]张根山,周胜利,张旭.原发性肝癌合并脾功能亢进的介入治疗[J].介入放射学杂志,2000,(03):183.
[3]钱晟,颜志平.门脉支架置放术治疗原发性肝癌伴门脉癌栓一例[J].介入放射学杂志,2000,(04):250.
[4]陈家焱,姬广翠,钱建华,等.原发性肝癌自发性破裂出血的介入治疗[J].介入放射学杂志,2008,(06):436.
　CHEN Jiayan,JI Guangcui,QIAN Jianhua,et al.Interventional treatment of primary liver cancer with spontaneous bleeding（３cases report）[J].J Intervent Med,2008,(03):436.
[5]曹跃勇,朱军,徐晓茜,等.原发性肝癌动脉栓塞术后螺旋CT和彩色多普勒超声比较和评价[J].介入放射学杂志,2008,(10):709.
　CAO Yueyong,ZHU Jun,XU Xiaoxi,et al.Comparison and evaluation between helical computer tomography and color－Doppler ultrasonography in primary hepatocellular carcinoma after transcatheter arterial chemoembolization[J].J Intervent Med,2008,(03):709.
[6]赵广生,徐克,梁松年,等.原发性肝癌TACE术后严重并发症原因及预防[J].介入放射学杂志,2008,(11):773.
　ZHAO Guangsheng,XU Ke,LIANG Songnian,et al.Causes and prevention of serious complication after transcatheter arterial chemoembolization for primary hepatic carcinoma[J].J Intervent Med,2008,(03):773.
[7]王执民,吴智群.中晚期原发性肝癌DSA表现的分型及其临床意义[J].介入放射学杂志,1997,(03):133.
[8]王邦浩.影响肝癌介入治疗效果的因素及对策[J].介入放射学杂志,1998,(03):170.
[9]邢丽华.原发性肝癌的介入治疗次数及单纯栓塞的意义[J].介入放射学杂志,1998,(03):166.
[10]邓力,陈庆强,卢秋红.华蟾素配合介入治疗原发性肝癌临床观察[J].介入放射学杂志,1999,(01):43.

备注/Memo

备注/Memo:
基金项目: 四川省医院协会县级医院科研专项资金项目(2023LC024)
通信作者: 姜永继 E-mail:578965408@qq.com
更新日期/Last Update: 2026-03-25